id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC11552228
core_pubmed_pmc
CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin
CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin Abstract Abstract Background A single nucleotide polymorphism (SNP) is a variation in the DNA sequence that results from the alteration of a single nucleotide in the genome. Atorvastatin...
PMC5824116
core_pubmed_pmc
Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations
Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations Abstract Abstract The unmet medical need of providing evidence‐based pharmacotherapy for pregnant women is recognized by the regulatory bodies. Physiologically based pharmacokinetic (PBPK)...
PMC10127981
core_pubmed_pmc
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults Abstract Introduction Adintrevimab is a fully human immunoglobulin G1 extended half-life mo...
PMC9294417
core_pubmed_pmc
Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference
Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference Abstract Abstract The cost of drug development continues to rise and may be prohibitive in cases of unmet clinical need, particularly for rare diseases. Artificial intelligence-based methods are promising in their potenti...
PMC12641605
core_pubmed_pmc
Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [ 14 C]JP-1366
Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [ 14 C]JP-1366 Abstract Introduction JP-1366 (zastaprazan), a novel potassium-competitive acid blocker (P-CAB), was approved in South Korea in 2024 for treatin...
PMC5449352
core_pubmed_pmc
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111 In-bevacizumab
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111 In-bevacizumab Abstract Abstract Background The ability to image vascular endothelial growth factor (VEGF) could enable prospective, non-invasive monitoring of patients receiving anti-angiogenic therapy. This study investigates the specific...
PMC10218654
core_pubmed_pmc
The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy Abstract Abstract Pharmacotherapy for neuropsychiatric disorders, such as anxiety and depression, has been characterized by significant inter-individual variability in drug response and the development of side effects. Pharmacogenet...
PMC11155120
core_pubmed_pmc
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination Abstract Abstract Background With only one 15 mg primaquine tablet registered by a stringent regulatory authority and marketed, more quality-assured primaquine is needed to meet the demands of malaria elimination. Methods A classic, two...
PMC8577399
core_pubmed_pmc
Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis
Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis Abstract Abstract Background The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of aminoglycoside antibiotics for the...
PMC9805718
core_pubmed_pmc
Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients
Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients Abstract Abstract Background Vancomycin is the best-choice medication for methicillin-resistant staphylococcal and enterococcal infections, which are major problems in intensive care units (ICUs). Intermittent infusion is standard fo...
PMC10651638
core_pubmed_pmc
Reconsideration of the current models of estimated kidney function‐based drug dose adjustment in older adults: The role of biological age
Reconsideration of the current models of estimated kidney function‐based drug dose adjustment in older adults: The role of biological age Abstract Abstract Human lifespan has increased from a median of 46.5 years in 1950 to 71.7 years in 2022. As people age, one of the inevitable consequences is a decline in kidney fun...
PMC10496854
core_pubmed_pmc
Pharmacokinetic Assessment of Pyrazinamide and Pyrazinoic Acid in Carbon tetrachloride-induced Liver Injury Model in Wistar Rats
Pharmacokinetic Assessment of Pyrazinamide and Pyrazinoic Acid in Carbon tetrachloride-induced Liver Injury Model in Wistar Rats Abstract A BSTRACT Background: We investigated the pharmacokinetic behavior of pyrazinamide (PZA) and pyrazinoic acid (PA) in the presence of carbon-tetrachloride (CCl 4 ) plus antitubercular...
PMC12228420
core_pubmed_pmc
Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics
Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics Abstract ABSTRACT The pharmacokinetics of vancomycin in neonates and infants exhibits significant variability, presenting challenges in achieving target exposures. This study aimed t...
PMC5029074
core_pubmed_pmc
Comparison of sedation strategies for critically ill patients: a protocol for a systematic review incorporating network meta-analyses
Comparison of sedation strategies for critically ill patients: a protocol for a systematic review incorporating network meta-analyses Abstract Abstract Background Sedatives and analgesics are administered to provide sedation and manage agitation and pain in most critically ill mechanically ventilated patients. Various ...
PMC11669282
core_pubmed_pmc
Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients
Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients Abstract Background and Objective Vancomycin is commonly prescribed in treatment of methicillin-resistant Staphylococcus aureus infections. While, vancomycins’ pharmacokinetic vary among older patie...
PMC11384495
core_pubmed_pmc
Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study
Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study Abstract Background Pembrolizumab 400 mg every six weeks (Q6W) and nivolumab 480 mg every four weeks (Q4W) are used since 2020 and the coronavirus disease 2019 (COVID-19) pandemic. This...
PMC11255119
core_pubmed_pmc
Pharmacokinetic effects of endoscopic gastric decontamination for multidrug gastric pharmacobezoars
Pharmacokinetic effects of endoscopic gastric decontamination for multidrug gastric pharmacobezoars Abstract Abstract Introduction Intentional multiple drugs overdose is an often-encountered method of self-harm in adolescence. Treatments include supportive therapy, antidotes (when available) and decontamination techniq...
PMC6394474
core_pubmed_pmc
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study Abstract Purpose To demonstrate the bioequivalence of the planned maleate salt-based commercial glasdegib tablet formulation [International Coun...
PMC9624457
core_pubmed_pmc
Pharmacogenetics of dolutegravir plasma exposure among Southern Africans living with HIV
Pharmacogenetics of dolutegravir plasma exposure among Southern Africans living with HIV Abstract Abstract Background Dolutegravir is a component of preferred antiretroviral therapy (ART) regimens. We characterised the pharmacogenetics of dolutegravir exposure following ART initiation in the ADVANCE trial in South Afri...
PMC3545186
core_pubmed_pmc
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo Abstract Actinomycin D plays a key role in the successful treatment of Wilms tumour. However, associated liver toxicities remain a drawback to potentially curative treatment. We hav...
PMC11080651
core_pubmed_pmc
Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs
Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs Abstract Cannabidiol (CBD) is a natural phytochemical agent and one of the most abundant found in Cannabis sativa . It is known to exhibit pharmacological properties on various condition such as relieving-inflammatio...
PMC5421745
core_pubmed_pmc
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies Modeling MODELING AND SIMULATION APPROACHES Model‐based approaches increasingly support decisions spanning the entire drug development process, from preclinical development through postmarketing, as shown in Figure 2 . The application of such appr...
PMC4773293
core_pubmed_pmc
Pharmacokinetic analysis of gefitinib in a patient with advanced non‐small cell lung cancer undergoing hemodialysis
Pharmacokinetic analysis of gefitinib in a patient with advanced non‐small cell lung cancer undergoing hemodialysis Abstract Abstract Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elde...
PMC8214532
core_pubmed_pmc
Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics
Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics Abstract Abstract Background An efficient, fast and sensitive ultra high-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) method for simultaneous determi...
PMC10664035
core_pubmed_pmc
What is the right gentamicin dose for multiple trauma patients? A Monte Carlo simulation exploration study
What is the right gentamicin dose for multiple trauma patients? A Monte Carlo simulation exploration study Abstract ABSTRACT Background: The appropriate dose of gentamicin is important to prevent and treat infections. The study aimed to determine the optimal dose of gentamicin to achieve the probability of pharmacokine...
PMC9796293
core_pubmed_pmc
Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia
Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia Abstract Abstract Aims To improve the tolerability and therapeutic application of histone deacetylase inhibitors (HDACi), by application of an esterase‐sensitive motif (ESM)...
PMC7590384
core_pubmed_pmc
The Adequateness of Methadone for Japanese Terminal Cancer Patients Can Be Determined Earlier than 7 Days: A Preliminary Retrospective Study
The Adequateness of Methadone for Japanese Terminal Cancer Patients Can Be Determined Earlier than 7 Days: A Preliminary Retrospective Study Abstract Abstract Introduction: The Japanese packaging instructions for methadone prohibit dose escalation within 7 days of administration initiation as this may result in overdos...
PMC4942950
core_pubmed_pmc
Public health and chronic low chlordecone exposure in Guadeloupe, Part 1: hazards, exposure-response functions, and exposures
Public health and chronic low chlordecone exposure in Guadeloupe, Part 1: hazards, exposure-response functions, and exposures Abstract Abstract Background Inhabitants of Guadeloupe are chronically exposed to low dose of chlordecone via local food. The corresponding health impacts have not been quantified. Nevertheless ...
PMC11279872
core_pubmed_pmc
From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt
From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt Abstract Abstract Pharmacogenomics (PGx) is the hope for the full optimization of drug therapy while minimizing the accompanying adverse drug events that cost billions of dollars annually. Since...
PMC4075372
core_pubmed_pmc
Concentration of Non-Steroidal Anti-Inflammatory Drugs in the Pelvic Floor Muscles: An Experimental Comparative Rat Model
Concentration of Non-Steroidal Anti-Inflammatory Drugs in the Pelvic Floor Muscles: An Experimental Comparative Rat Model Abstract Purpose The aim of this study is to explore non-steroid anti-inflammation drugs (NSAIDs) potency for pelvic floor muscle pain by measuring local concentration in a rat model. Materials and ...
PMC9804870
core_pubmed_pmc
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors Abstract Abstract Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or p...
PMC11678822
core_pubmed_pmc
Unveiling the Potential of C max f 2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products
Unveiling the Potential of C max f 2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies—A Case Study with Pazopanib Drug Products Abstract Abstract Background: When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out...
PMC11181332
core_pubmed_pmc
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases Abstract Abstract Tyrosine kinase 2 (TYK2) mediates cytokine signaling through type 1 interferon, interleukin (IL)-12/IL-23, and the IL-10 family. There appears to be an association between TYK2 genet...
PMC7070911
core_pubmed_pmc
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years Abstract Abstract Background: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been reached ...
PMC10221159
core_pubmed_pmc
Investigation of N -Acetyltransferase 2-Mediated Drug Interactions of Amifampridine: In Vitro and In Vivo Evidence of Drug Interactions with Acetaminophen
Investigation of N -Acetyltransferase 2-Mediated Drug Interactions of Amifampridine: In Vitro and In Vivo Evidence of Drug Interactions with Acetaminophen Abstract Amifampridine is a drug used for the treatment of Lambert–Eaton myasthenic syndrome (LEMS) and was approved by the Food and Drug Administration (FDA) of the...
PMC10828317
core_pubmed_pmc
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies
A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies Abstract Abstract Introduction COVID-19 remains a significant risk for the immunocompromised given their lower responsiveness to vac...
PMC12126198
core_pubmed_pmc
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial Abstract Summary Background In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor–tezacaftor–deutivacaftor has been shown to...
PMC4665607
core_pubmed_pmc
Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics Abstract Radium-223-dichloride ( 223 RaCl 2 ) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for th...
PMC4238785
core_pubmed_pmc
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers Abstract Abstract Aims Two clinical studies were conducted to determine possible drug−drug interactions between apremilast and a strong CYP3A4 inhibitor, ketoconazole, or a potent CYP3A4 inducer, r...
PMC11196052
core_pubmed_pmc
Ropivacaine pharmacokinetics in the arterial and venous pools after ultrasound-guided continuous thoracic paravertebral nerve block
Ropivacaine pharmacokinetics in the arterial and venous pools after ultrasound-guided continuous thoracic paravertebral nerve block Abstract Background and Aims: Although thoracic paravertebral blockade (TPVB) is employed in thoracic surgery to ensure satisfactory postoperative analgesia, large doses of anesthetics are...
PMC8510344
core_pubmed_pmc
Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats
Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats Abstract Abstract A library of bile-acid-appended triazolyl aryl ketones was synthesized and characterized by detailed spectroscopic techniques such as 1 H and 13 C NMR, HRMS and HPLC. All the synthes...
PMC5132104
core_pubmed_pmc
Improved method for quantitative analysis of the cyclotide kalata B1 in plasma and brain homogenate
Improved method for quantitative analysis of the cyclotide kalata B1 in plasma and brain homogenate Abstract Abstract This study provides a new method for quantifying the cyclotide kalata B1 in both plasma and brain homogenate. Cyclotides are ultra‐stable peptides with three disulfide bonds that are interesting from a ...
PMC10604144
core_pubmed_pmc
The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer’s Disease
The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer’s Disease Abstract The use of cannabinoids (substances contained specifically in hemp plants) for therapeutic purposes has received increased attention in recent years. Presently, attention is paid to two...
PMC9366251
core_pubmed_pmc
Pharmacological profiles and therapeutic applications of pachymic acid (Review)
Pharmacological profiles and therapeutic applications of pachymic acid (Review) Abstract Poria cocos is a saprophytic fungus that grows in diverse species of Pinus . Its sclerotium, called fu-ling or hoelen, has been used in various traditional Chinese medicines and health foods for thousands of years, and in several m...
PMC10006255
core_pubmed_pmc
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes Abstract Background Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decom...
PMC3908832
core_pubmed_pmc
Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics
Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics Abstract Abstract The nanoparticle drug delivery system, which uses natural or synthetic polymeric material as a carrier to deliver drugs to targeted tissues, has a broad prospect for clinical application...
PMC5761358
core_pubmed_pmc
Simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by LC–ESI-MS/MS and its application to pharmacokinetics in rats
Simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by LC–ESI-MS/MS and its application to pharmacokinetics in rats Abstract Abstract Polypill is a fixed-dose combination that contains three or more active ingredients used as a single daily pill to achieve a large effect in preventing cardiovasc...
PMC8237188
core_pubmed_pmc
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib Abstract Objective Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially rela...
PMC12811208
core_pubmed_pmc
Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial Abstract Abstract Intestinal failure‐associated liver disease occurs in 20% to 30% of patients with short bowel syndrome and intestinal failure (SBS‐IF). Apraglutide is a glucagon...
PMC7308427
core_pubmed_pmc
Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate
Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate Abstract Abstract Introduction: High dose methotrexate (HD-Mtx) is highly effective and significantly...
PMC4967996
core_pubmed_pmc
The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial
The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial Abstract Abstract Background The promotility agents currently available to treat gastroparesis and feed intolerance in ...
PMC11787888
core_pubmed_pmc
Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model
Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model Abstract Abstract Background Murine pneumonia models play a fundamental role in the preclinical development of novel compounds seeking an i...
PMC8145331
core_pubmed_pmc
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection Abstract Abstract Praziquantel (PZQ) and dihydroartemisinin-piperaquine (DHP) combination recently showed superior effectiveness than PZQ alone to treat intestinal schistosomiasis. In this fol...
PMC10723162
core_pubmed_pmc
Ursolic acid derivative UAOS-Na treats experimental autoimmune encephalomyelitis by immunoregulation and protecting myelin
Ursolic acid derivative UAOS-Na treats experimental autoimmune encephalomyelitis by immunoregulation and protecting myelin Abstract Abstract Introduction Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Ursolic acid (UA) can be used in the MS treatment with anti-infl...
PMC7200043
core_pubmed_pmc
Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria
Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria Abstract Introduction Lassa fever (LF) is a severe and often fatal systemic disease in humans and affects a large number of countries in West Africa....
PMC4055595
core_pubmed_pmc
Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san : From the Perspective of P-Glycoprotein
Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san : From the Perspective of P-Glycoprotein Abstract Abstract Background Phytochemical-mediated alterations in P-glycoprotein (P-gp) activity may result in herb-drug interactions by altering drug pharmacokinetics. Shengmai-san , a traditi...
PMC5817390
core_pubmed_pmc
An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure
An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure Abstract Edoxaban and its low-abundance, active metabolite M4 are substrates of P-glycoprotein (P-gp; MDR1) and organic anion transporter protein 1B1 (OATP1B1), respectively, and pharmacological inhibitors of ...
PMC8879752
core_pubmed_pmc
Free and Open-Source Posologyr Software for Bayesian Dose Individualization: An Extensive Validation on Simulated Data
Free and Open-Source Posologyr Software for Bayesian Dose Individualization: An Extensive Validation on Simulated Data Abstract Abstract Model-informed precision dosing is being increasingly used to improve therapeutic drug monitoring. To meet this need, several tools have been developed, but open-source software remai...
PMC12669303
core_pubmed_pmc
A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics and Safety of Dotinurad in Healthy Chinese Adults
A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics and Safety of Dotinurad in Healthy Chinese Adults Abstract Background and Objectives Dotinurad is a selective uricosuric drug for patients with gout with hyperuricemia. To our knowledge, this is the first study to evaluate the pharmacokinetics (PK) ...
PMC9796421
core_pubmed_pmc
Global trends of dalbavancin: A bibliometric analysis
Global trends of dalbavancin: A bibliometric analysis Abstract Abstract What is known and objective? Dalbavancin is used against gram‐positive pathogens such as Staphylococcus aureus in acute bacterial skin and skin‐structure infections. Methods Our main goal was to identify the key articles sustaining the current know...
PMC12250197
core_pubmed_pmc
Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy
Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy Abstract Tumor stiffness is a critical factor influencing cancer progression, therapeutic resistance, and drug delivery. This study investigates the role of mechanical normalization in breast cancer the...
PMC8227626
core_pubmed_pmc
Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives
Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives Abstract Clinical evidence suggests that nebulized colistimethate sodium (CMS) has benefits for treating lower respiratory tract infections caused by multidrug-resistant Gram-negative ba...
PMC10514397
core_pubmed_pmc
Cyphenothrin (Veterinary Medicinal Products)
Cyphenothrin (Veterinary Medicinal Products) Abstract Abstract Food Safety Commission of Japan (FSCJ) conducted a risk assessment of cyphenothrin (CAS No. 39515-40-7), a pyrethroid insecticide, intended to be used to exterminate cockroaches in piggeries. This was based on documents of pigsty sprays containing the activ...
PMC12030460
core_pubmed_pmc
From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets
From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets Abstract Background : Candesartan cilexetil, a Biopharmaceutics Classification System (BCS) II prodrug, demonstrates compromised bioavailability attributable to its limited aqueous s...
PMC3925586
core_pubmed_pmc
Evaluation of the Cerebral State Index in Cats under Isoflurane Anaesthesia: Dose-Effect Relationship and Prediction of Clinical Signs
Evaluation of the Cerebral State Index in Cats under Isoflurane Anaesthesia: Dose-Effect Relationship and Prediction of Clinical Signs Abstract The performance of the cerebral state index (CSI) in reflecting different levels of isoflurane anaesthesia was evaluated in ten cats subjected to four end-tidal isoflurane conc...
PMC7036053
core_pubmed_pmc
A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects
A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects Abstract Purpose This is the first study to compare the pharmacokinetics of QL1101, a proposed bevacizumab biosimilar, with Avastin ® sourced from Roche Diagnostics GmbH. Methods In this doubl...
PMC11629255
core_pubmed_pmc
Pharmacokinetics of pradofloxacin, florfenicol, and tulathromycin and response to treatment of steers experimentally infected with Mannheimia hemolytica
Pharmacokinetics of pradofloxacin, florfenicol, and tulathromycin and response to treatment of steers experimentally infected with Mannheimia hemolytica Abstract Abstract Background Bovine respiratory disease (BRD) is an economically important disease in the beef industry, and a major driver of therapeutic antibiotic u...
PMC9279852
core_pubmed_pmc
Biological impact of iberdomide in patients with active systemic lupus erythematosus
Biological impact of iberdomide in patients with active systemic lupus erythematosus Abstract Abstract Objectives Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of transcription factors Ikaros ( IKZF1 ) and Aiolos ( IKZF3 ). Pharmacodynamics and pharmacokinetics of oral iberdomide w...
PMC7977375
core_pubmed_pmc
Simultaneous determination of two galangin metabolites from Alpinia Officinarum Hance in rat plasma by UF LC-MS/MS and its application in pharmacokinetics study
Simultaneous determination of two galangin metabolites from Alpinia Officinarum Hance in rat plasma by UF LC-MS/MS and its application in pharmacokinetics study Abstract Abstract Galangin has multiple pharmacological efficacies, such as anti-cancer, anti-inflammation and anti-oxidation. Galangin can be rapidly converte...
PMC10333647
core_pubmed_pmc
Likelihood interval for nonlinear regression
Likelihood interval for nonlinear regression Abstract Wald confidence interval has been used as the conventional method of interval estimation for the parameters in nonlinear models. Because Wald confidence interval is symmetric around the point estimate, it does not reflect the asymmetry of the likelihood profile in n...
PMC4032181
core_pubmed_pmc
Biomarker-Based Calibration of Retrospective Exposure Predictions of Perfluorooctanoic Acid
Biomarker-Based Calibration of Retrospective Exposure Predictions of Perfluorooctanoic Acid Abstract Estimated historical exposures and serum concentrations of perfluorooctanoic acid (PFOA) have been extensively used in epidemiologic studies that examined associations between PFOA exposures and adverse health outcomes ...
PMC11824839
core_pubmed_pmc
Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii –Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii –Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Abstract Abstract Purpose: To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial a...
PMC6248227
core_pubmed_pmc
Fabricating polydopamine-coated MoSe 2 -wrapped hollow mesoporous silica nanoplatform for controlled drug release and chemo-photothermal therapy
Fabricating polydopamine-coated MoSe 2 -wrapped hollow mesoporous silica nanoplatform for controlled drug release and chemo-photothermal therapy Abstract Background Integration of several types of therapeutic agents into one nanoplatform to enhance treatment efficacy is being more widely used for cancer therapy. Method...
PMC11004028
core_pubmed_pmc
Morphine concentrations in fatalities after palliative treatment of acute burn injury
Morphine concentrations in fatalities after palliative treatment of acute burn injury Abstract The evaluation of a morphine concentration in postmortem blood is routine for a forensic toxicologist. We here report three fatal cases where we found high morphine concentrations with 7.96, 4.30, and 5.82 mg/l in femoral blo...
PMC11859819
core_pubmed_pmc
Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats
Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats Abstract Background/Objectives : Bacteria are becoming increasingly resistant to levofloxacin and other fluoroquinolones. Previously, drug loading in colloidal carriers has shown enhanced penetration into and r...
PMC10764490
core_pubmed_pmc
Evaluation of NTP42 , a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial
Evaluation of NTP42 , a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial Abstract Background: The thromboxane receptor (TP) antagonist NTP42 is in clinical development for treatment of cardiopulmonary diseases, such as pulmonary arterial hypertension. In this randomized, placebo-control...
PMC3888620
core_pubmed_pmc
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients Abstract Abstract Objective To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-α monoclonal anti...
PMC10135418
core_pubmed_pmc
Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo
Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo Abstract Abstract Purpose The present study aimed to construct a co-loading platform encapsulating curcumin and paclitaxel at ratios of 2:1–80:1 (w/w) designated “CU-P...
PMC9007608
core_pubmed_pmc
Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability
Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability Abstract Abstract Among the current approaches for the analysis of bioequivalence, the average bioequivalence (ABE) is limited only to the mean bioavailability, ...
PMC5447445
core_pubmed_pmc
Pharmacokinetics of a liposomal formulation of doxorubicin in rats
Pharmacokinetics of a liposomal formulation of doxorubicin in rats Abstract Abstract Background: Measuring free drug concentration following systemic administration of a liposomal drug is a crucial aspect of the assessment of its in vivo behavior. Therefore we require an efficient method to separate free drug in the pl...
PMC6332596
core_pubmed_pmc
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors Abstract Abstract Background Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGF...
PMC9024636
core_pubmed_pmc
Formulation and Evaluation of Transdermal Gel Containing Tacrolimus-Loaded Spanlastics: In Vitro , Ex Vivo and In Vivo Studies
Formulation and Evaluation of Transdermal Gel Containing Tacrolimus-Loaded Spanlastics: In Vitro , Ex Vivo and In Vivo Studies Abstract Our goal was to prepare Span 60-based elastic nanovesicles (spanlastics (SPLs)) of tacrolimus (TCR) using the adapted ethanol injection method, characterize them, and evaluate their ab...
PMC8194824
core_pubmed_pmc
Case Report of Novel Genetic Variant in KCNT1 Channel and Pharmacological Treatment With Quinidine. Precision Medicine in Refractory Epilepsy
Case Report of Novel Genetic Variant in KCNT1 Channel and Pharmacological Treatment With Quinidine. Precision Medicine in Refractory Epilepsy Abstract Case introduction: In this work we present a female infant patient with epilepsy of infancy with migrating focal seizures (EIMFS). Although many pharmacological schemes ...
PMC12464896
core_pubmed_pmc
Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications
Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications Abstract ABSTRACT Lisdexamfetamine (LDX), a prodrug of d ‐amphetamine, is widely used in the pharmacological treatment of neuropsychiatric disorders such as attention‐deficit/hyperactivity disorder (ADHD) ...
PMC9291832
core_pubmed_pmc
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers Abstract Aims The pharmacokinetic (PK) similarity between MB02, a proposed bevacizumab biosimilar, and reference bevacizumab...
PMC11959975
core_pubmed_pmc
A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement
A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement Abstract Ischemic stroke (IS) is a globally life-threatening disease. Presently, few therapeutic medicines are available for treating IS, and rt-PA is the only drug approved by the US Food and Drug ...
PMC11652805
core_pubmed_pmc
A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition
A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition Abstract Abstract Data published on the oral clavulanic acid pharmacokinetics in the pediatric population is lacking. This research aimed to describe...
PMC4300367
core_pubmed_pmc
Clinical Pharmacokinetics and Effects of Vincristine Sulfate in Dogs with Transmissible Venereal Tumor (TVT)
Clinical Pharmacokinetics and Effects of Vincristine Sulfate in Dogs with Transmissible Venereal Tumor (TVT) Abstract This study was conducted to evaluate the pharmacokinetic characteristics of vincristine and their correlation with its clinical effects in dogs with transmissible venereal tumor (TVT). Dogs with TVT wer...
PMC8230281
core_pubmed_pmc
Improving the Pharmacological Properties of Ciclopirox for Its Use in Congenital Erythropoietic Porphyria
Improving the Pharmacological Properties of Ciclopirox for Its Use in Congenital Erythropoietic Porphyria Abstract Abstract Congenital erythropoietic porphyria (CEP), also known as Günther’s disease, results from a deficient activity in the fourth enzyme, uroporphyrinogen III synthase (UROIIIS), of the heme pathway. Ci...
PMC6375702
core_pubmed_pmc
Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia
Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia Abstract Abstract Objective Morphine is a commonly used drug in encephalopathic neonates treated with therapeutic hypothermia after perinatal asphyxia. Pharmacokinetics and optimal dosing of morphine in this population are lar...
PMC12133927
core_pubmed_pmc
Pharmacogenomics of TNF inhibitors
Pharmacogenomics of TNF inhibitors Abstract Abstract Tumor necrosis factor alpha inhibitors (TNFi) are biologic drugs that target TNFα, a key pro-inflammatory cytokine, to suppress disease activity and alleviate symptoms of various autoimmune diseases, including inflammatory bowel disease. This review focuses on the fi...
PMC10980040
core_pubmed_pmc
PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [ 11 C]WAY100635 Overcomes Outcome Measure Discrepancies
PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [ 11 C]WAY100635 Overcomes Outcome Measure Discrepancies Abstract Abstract The serotonin 1A receptor has been linked to both the pathophysiology of major depressive disorder (MDD) and the antidepressant action o...
PMC12730921
core_pubmed_pmc
Digital Twins for Radiopharmaceutical Dosimetry: PBPK Modelling of [ 177 Lu]Lu-rhPSMA-10.1 in a Preclinical mCRPC Model
Digital Twins for Radiopharmaceutical Dosimetry: PBPK Modelling of [ 177 Lu]Lu-rhPSMA-10.1 in a Preclinical mCRPC Model Abstract Simple Summary This paper presents a mouse-specific physiologically based pharmacokinetic (PBPK) model to generate digital twins for dosimetric evaluation of [ 177 Lu]Lu-rhPSMA-10.1, a radiop...
PMC3148475
core_pubmed_pmc
Pharmacokinetics of cephalosporins in the neonate: a review
Pharmacokinetics of cephalosporins in the neonate: a review Abstract Abstract The aim of this work was to review the published data on the pharmacokinetics of cephalosporins in neonates to provide a critical analysis of the literature as a useful tool for physicians. The bibliographic search was performed for articles ...
PMC4735712
core_pubmed_pmc
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma Abstract The purpose of the present study was to investigate whether genetic variants that influence angiogenesis and sorafenib pharmacokinetics are associated with clinical outcomes and ...
PMC10984053
core_pubmed_pmc
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease Abstract Background: Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease...
PMC12687882
core_pubmed_pmc
Increased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model
Increased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model Abstract Monoclonal antibodies (mAbs) are powerful therapeutic tools that are used to treat multiple types of human cancer as well as a diverse set of non-malignant diseases. Humanized NOD.Cg- Prkdc scid Il2rgt m1...
PMC5913287
core_pubmed_pmc
In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Danofloxacin in Rabbits Infected With Salmonella typhimurium After Oral Administration
In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Danofloxacin in Rabbits Infected With Salmonella typhimurium After Oral Administration Abstract Abstract Salmonella typhimurium is a highly transmissible pathogen in rabbits that causes significant losses. Danofloxacin shows excellent efficacy against S. typhimurium i...
PMC12655050
core_pubmed_pmc
Cracking the Sulfur Code: Garlic Bioactive Molecules as Multi-Target Blueprints for Drug Discovery
Cracking the Sulfur Code: Garlic Bioactive Molecules as Multi-Target Blueprints for Drug Discovery Abstract Garlic ( Allium sativum L.) has served as a food source and medicinal agent for over thousands of years. Bioactive constituents, including allicin, diallyl sulfide/disulfide/trisulfide, ajoene, and S -allyl-cyste...
PMC6669187
core_pubmed_pmc
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets Abstract Background An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson’s disease and drug-induced extrapyramidal reactions in ad...